Skip to main content
SpringerLink
Log in

Role of Interleukin-28B Polymorphism as a Predictor of Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Triple Therapy: A Systematic Review and Meta-Analysis

  • Systematic Review
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and Objective

Chronic hepatitis C represents an important health problem. The aim of our meta-analysis was to establish the role of reference single nucleotide (rs) 12979860 allele of interleukin-28B (IL28B) CC versus CT+TT genotype (the most researched allele of IL28B) as a predictor of sustained virological response (SVR) in patients with chronic hepatitis C treated with triple therapy.

Methods

The PubMed, MEDLINE, Lilacs, Scopus, Ovid, EMBASE, Cochrane and Medscape databases as well as abstract books from important gastroenterology and hepatology meetings were searched for all studies published until 15 July 2012 that analysed the relationship between the polymorphism of IL28B and SVR in patients with chronic hepatitis C, genotype 1, treated with pegylated interferon + ribavirin + direct antiviral agents (telaprevir or boceprevir). The following keywords were used: IL28B polymorphism, chronic hepatitis C, sustained virological response, SVR, triple therapy, telaprevir, boceprevir.

Results

Odds ratios (ORs) with 95 % confidence intervals were pooled from five study populations (1,641 cases) using a random–effects model. The SVR rate was significantly higher in patients with the CC genotype of IL28B than in those with non-CC genotypes (CT and TT): OR = 3.91 (95 % CI 2.11–7.28), p < 0.0001. Higher SVR rates were obtained in chronic hepatitis C patients with the CC genotype of IL28B, regardless of their therapeutic status (naïve patients: OR = 3.99 [95 % CI 1.67–9.51], p < 0.0001; and previously treated ones: OR = 2.15 [95 % CI 1.35–3.43], p = 0.001).

Conclusion

IL28B polymorphism seems to influence the SVR rate in patients with chronic hepatitis C treated with triple therapy, but further studies are needed to clarify the mechanism and the influence of other factors on the SVR rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. WHO. Global surveillance and control of Hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Liver. 1999;6(1):34–5.

    Google Scholar 

  2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65.

    Article  PubMed  CAS  Google Scholar 

  3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–55.

    Article  PubMed  CAS  Google Scholar 

  4. Sporea I, Sirli R, Curescu M, et al. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis: a retrospective study in 507 patients. J Gastrointestin Liver Dis. 2010;19(3):261–4.

    PubMed  Google Scholar 

  5. Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 2012;56(6):2039–50.

    Article  PubMed  CAS  Google Scholar 

  6. Bota S, Sporea I, Popescu A, et al. Response to standard of care antiviral treatment in patients with HCV liver cirrhosis: a systematic review. J Gastrointestin Liver Dis. 2011;20(3):293–8.

    PubMed  Google Scholar 

  7. Syed E, Rahbin N, Weiland O, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh A liver cirrhosis. Scand J Gastroenterol. 2008;43(11):1378–86.

    Article  PubMed  CAS  Google Scholar 

  8. Fernandez-Rodriguez C, Alonso S, Martinez SM, et al. PegInterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105(10):2164–72.

    Article  PubMed  CAS  Google Scholar 

  9. Rauch A, Kutalik Z, Descombes P, et al. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338–45.

    Google Scholar 

  10. Grebely J, Petoumenos K, Hellard M, et al. ATAHC Study Group. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52(4):1216–24.

    Google Scholar 

  11. Li S, Hu P, Zhang QQ, et al. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-Interferon/ ribavirin therapy: a meta-analysis. Hepat Mon. 2011;11(3):163–72.

    PubMed  CAS  Google Scholar 

  12. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Aliment Pharmacol Ther. 2012;36(2):91–103.

    Article  PubMed  CAS  Google Scholar 

  13. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2011;8(5):257–64.

    PubMed  CAS  Google Scholar 

  14. McHutchison JG, Manns MP, Muir AJ, et al. PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362(14):1292–330.

    Google Scholar 

  15. Smith LS, Nelson M, Naik S, Woten J. Telaprevir: an NS3/4A Protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother. 2011;45(5):639–48.

    Article  PubMed  CAS  Google Scholar 

  16. Poordad F, McCone J Jr, Bacon BR, et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.

    Google Scholar 

  17. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011;140(2):459–68.

    Article  PubMed  CAS  Google Scholar 

  18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

    Article  PubMed  CAS  Google Scholar 

  19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

    Article  PubMed  CAS  Google Scholar 

  20. Chayama K, Nelson Hayes C, Abe H. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204(1):84–93.

    Article  PubMed  CAS  Google Scholar 

  21. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, et al. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology. 2012;55(3):231–41.

    Article  PubMed  CAS  Google Scholar 

  22. Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decrease of hemoglobin during treatment with pegylated interferon, ribavirin and telaprevir. Hepatology. 2011;53(2):415–21.

    Article  PubMed  CAS  Google Scholar 

  23. Poordad F, Bronowicki JP, Gordon SC, et al. SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143(3):608–18.

    Google Scholar 

  24. Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study [abstract]. J Hepatol. 2011;54(Suppl 1):S6.

    Article  Google Scholar 

  25. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial [abstract]. J Hepatol. 2011;54(Suppl 1):S542.

    Article  Google Scholar 

  26. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the Interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52(2):421–9.

    Article  PubMed  CAS  Google Scholar 

  27. Bronowicki JP, Hezode C, Bengtsson L, et al. 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial [abstract]. J Hepatol. 2012;56(Suppl 2):S430.

    Article  Google Scholar 

  28. Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207–17.

    Google Scholar 

  29. Zeuzem S, Andreone P, Pol S; REALIZE Study Team, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–28.

  30. Jacobson IM, McHutchison JG, Dusheiko G, et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16.

    Google Scholar 

  31. Hézode C, Forestier N, Dusheiko G, et al. PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839–50.

    Google Scholar 

  32. Mauss S, Hueppe D, John C, et al. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat. 2011;18(4):e81–90.

    Article  PubMed  CAS  Google Scholar 

  33. Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hep. 2008;15(2):129–36.

    CAS  Google Scholar 

  34. Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig. 2008;28(1):9–16.

    Article  PubMed  CAS  Google Scholar 

  35. Fried MW, Hadziyannis SJ, Shiffman ML, et al. Rapid virological response is the most important predictor of virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011;55(1):69–75.

    Article  PubMed  Google Scholar 

  36. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.

    Article  PubMed  CAS  Google Scholar 

  37. Sporea I, Popescu A, Curescu M, et al. The correlation of Il28B genotype with sustained virologic response in Romanian patients with chronic hepatitis C. Hepat Mon. 2011;11(12):975–9.

    Article  PubMed  Google Scholar 

  38. McHutchison JG. The role of genetic markers in hepatitis C virus therapy: a major step to individualized care. Liver Int. 2011;31(Suppl 1):29–35.

    Article  PubMed  Google Scholar 

  39. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005;128(5):1437–44.

    Article  PubMed  CAS  Google Scholar 

  40. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008;105(19):7034–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

None of the authors have any conflict of interests. No funding support was received for this study.

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, “Victor Babeş” University of Medicine and Pharmacy, 10, Iosif Bulbuca Blv., 300736, Timisoara, Romania

    Simona Bota, Ioan Sporea, Roxana Şirli, Alina Popescu & Mihnea Străin

  2. Department of Biochemistry, “Victor Babeş” University of Medicine and Pharmacy, 10, Iosif Bulbuca Blv., 300736, Timisoara, Romania

    Adriana Maria Neghină

Authors
  1. Simona Bota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ioan Sporea
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roxana Şirli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adriana Maria Neghină
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alina Popescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mihnea Străin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simona Bota.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bota, S., Sporea, I., Şirli, R. et al. Role of Interleukin-28B Polymorphism as a Predictor of Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Triple Therapy: A Systematic Review and Meta-Analysis. Clin Drug Investig 33, 325–331 (2013). https://doi.org/10.1007/s40261-013-0074-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-013-0074-0

Keywords

Search

Navigation